194 related articles for article (PubMed ID: 25522335)
41. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer.
Ettl T; Baader K; Stiegler C; Müller M; Agaimy A; Zenk J; Kühnel T; Gosau M; Zeitler K; Schwarz S; Brockhoff G
Br J Cancer; 2012 Feb; 106(4):719-26. PubMed ID: 22240798
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
43. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.
Koivisto P; Hyytinen E; Palmberg C; Tammela T; Visakorpi T; Isola J; Kallioniemi OP
Am J Pathol; 1995 Dec; 147(6):1608-14. PubMed ID: 7495286
[TBL] [Abstract][Full Text] [Related]
44. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Jeong ISD; Moyers J; Thung I; Thinn MM
Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
[TBL] [Abstract][Full Text] [Related]
45. [Androgen receptor-positive triple negative breast cancer: From biology to therapy].
Grellety T
Bull Cancer; 2020 Apr; 107(4):506-516. PubMed ID: 32145961
[TBL] [Abstract][Full Text] [Related]
46. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
Okegawa T; Nutahara K; Higashihara E
Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
[TBL] [Abstract][Full Text] [Related]
47. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
Molenaar JP; Baten A; Blokx WA; Hoogendam A
Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417
[TBL] [Abstract][Full Text] [Related]
48. The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapy.
Dalgleish AG; Di Palma S; Nathan K; Powell B; Patel N; Fusi A
Eur J Cancer; 2019 May; 113():14-18. PubMed ID: 30954882
[No Abstract] [Full Text] [Related]
49. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
50. [Hormonal therapy for prostate cancer: methods and prognosis].
Huang BX; Su HC; Cao WL; Sun FK
Zhonghua Nan Ke Xue; 2013 Sep; 19(9):815-9. PubMed ID: 24386861
[TBL] [Abstract][Full Text] [Related]
51. Androgen deprivation therapy for metastatic salivary gland cancer.
Elkrief A; Saleh R
CMAJ; 2018 Aug; 190(33):E985-E987. PubMed ID: 30127038
[No Abstract] [Full Text] [Related]
52. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
53. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
54. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
55. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
56. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Vessella RL; Vicentini C; Bologna M
Endocr Relat Cancer; 2007 Sep; 14(3):601-11. PubMed ID: 17914091
[TBL] [Abstract][Full Text] [Related]
57. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP
Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963
[TBL] [Abstract][Full Text] [Related]
58. Oral bicalutamide for female pattern hair loss: A pilot study.
Fernandez-Nieto D; Saceda-Corralo D; Rodrigues-Barata R; Hermosa-Gelbard A; Moreno-Arrones O; Jimenez-Cauhe J; Ortega-Quijano D; Vano-Galvan S
Dermatol Ther; 2019 Nov; 32(6):e13096. PubMed ID: 31579984
[No Abstract] [Full Text] [Related]
59. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
[TBL] [Abstract][Full Text] [Related]
60. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
